▼ JEMPERLI (dostarlimab) logo

Product menu

Image of Black Woman gardening

JEMPERLI + CP demonstrates a statistically significant (p<0.0001) and clinically meaningful PFS benefit vs placebo + CP in dMMR/MSI-H primary advanced or recurrent EC1,2 

DISCOVER THE RUBY TRIAL
Image of lightbulb held by patient and healthcare professional

JEMPERLI is already licensed as a monotherapy for patients with advanced or recurrent dMMR/MSI-H endometrial cancer who have progressed on or following platinum-based chemotherapy, in whom it demonstrated durable efficacy for more than 2 years1

Image of percentage of dMMR/MSI-H in EC

of endometrial cancers are dMMR/MSI-H3

dMMR/MSI-H is an important biomarker that can help to personalise endometrial cancer treatment4

Guidelines recommend testing patients with endometrial cancer for dMMR/MSI-H5,6

Response Rate Icon

Jemperli Efficacy

JEMPERLI + CP demonstrates a statistically significant (p<0.0001) and clinically meaningful PFS benefit vs placebo + CP in dMMR/MSI-H primary advanced or recurrent EC2

VIEW THE EVIDENCE >
Safety Icon

Jemperli Safety Profile

JEMPERLI + CP offers a manageable safety profile consistent with the known profiles of its individual components after 2 years of follow-up1,2

EXPLORE THE DATA >
Dosing and Administration Icon

Dosing & Treatment Management

The recommended dose of JEMPERLI as part of combination therapy is 500 mg every 3 weeks for 6 cycles followed by 1000 mg every 6 weeks thereafter1

LEARN MORE >
Explore the Resource Library

Access Healthcare Professional Resources

Access Patient-Facing Resources

Do you have questions about how JEMPERLI can support your patients?

GET IN TOUCH

Indications

JEMPERLI is indicated in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.

JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinumcontaining regimen.

Footnotes

CP, carboplatin/paclitaxel; dMMR, mismatch repair deficient; EC, endometrial cancer; MSI-H, microsatellite instability-high.

References

  1. Jemperli (dostarlimab) Summary of Product Characteristics, Great Britain. Accessed October 2023.
  2. Mirza MR, et al. Dostarlimab for primary advanced recurrent endometrial cancer. N Eng J Med. 2023;388(23):2145-2158
  3. Green AK, et al. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:1-7
  4. Song Y, et al. Endometrial tumors with MSI-H and dMMR share a similar tumor immune microenvironment. Onco Targets Ther. 2021;14:4485-4497
  5. Oaknin A, et al. Endometrial Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2022;33(9):860-8
  6. National Institute for Health and Care Excellence. DG42. Testing strategies for Lynch syndrome in people with endometrial cancer. October 2020. Available from https://www.nice.org.uk/guidance/dg42 Accessed October 2023

Adverse events should be reported.
Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/ (UK) or search for MHRA Yellow Card in the Google Play or Apple App store.

Adverse events should also be reported to GSK Limited on 0800 221 441 or uksafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

January 2023 ӏ PM-GB-DST-WCNT-230013 (V1.0)